AXS-05 + Bupropion + Placebo
Phase 2/3Completed 0 watching 0 views this week📈 Rising
62
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Agitation in Patients With Dementia of the Alzheimer's Type
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor
Trial Timeline
Jul 13, 2017 → Apr 17, 2020
NCT ID
NCT03226522About AXS-05 + Bupropion + Placebo
AXS-05 + Bupropion + Placebo is a phase 2/3 stage product being developed by Axsome Therapeutics for Agitation in Patients With Dementia of the Alzheimer's Type. The current trial status is completed. This product is registered under clinical trial identifier NCT03226522. Target conditions include Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor.
Hype Score Breakdown
Clinical
22
Activity
15
Company
7
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03226522 | Phase 2/3 | Completed |
Competing Products
20 competing products in Agitation in Patients With Dementia of the Alzheimer's Type